摘要
目的了解成神经细胞瘤雌激素受体（ＥＲ），探索新疗法。方法运用酶联亲和组织化学法检测成神经细胞瘤２９例，选择３例ＥＲ阳性的Ⅳ期患儿，加用三苯氧胺治疗。结果ＥＲ阳性率５１７％（１５／２９）。其中＜１岁组阳性率为２／３（例），１～３岁为２／８（例），４～６岁为３／１０（例），７～１０岁为８／８（例）。病理预后较好类型者ＥＲ阳性率为１６７％（１／６），而预后差类型者为６８４％（１３／１９），显著高于前者（Ｐ＜００５）。３例患儿服用三苯氧胺后疼痛症状暂时缓解或存活期延长。结论成神经细胞瘤ＥＲ阳性率较高，ＥＲ可作为成神经细胞瘤预后的指标。三苯氧胺是潜在的治疗药物。
PURPOSE To evaluate estrogen receptor (ER) in neuroblastoma and to develop new methods of therapy.METHODS Enzymelinking affinity immunohistochemistry method was used to evaluate ER in 29 cases. Three cases with positive ER (ER+) Ⅳ stage tumors received tamoxifen treatment.RESULTS ER+ rate of the tumors was 51.7%(15/29). ER+ cases: aged<1 year, 2/3 cases; aged 1～3 years, 2/8 cases; aged 4～6 years, 3/10 cases, and aged 7～11 years, 8/8 cases, The ER+ rate of the cases with tumors of favorable histologic type was 16.7%(1/18), and that of the unfavorable type was 68.4%(13/19). Temporary relief of pain or prolonged survival was observed in the 3 cases treated by tamoxifen.CONCLUSIONS Our results suggest that ER+ rate is rather high in neuroblastoma. ER may be used as a prognostic marker, and tamoxifen as a potential treatment for this malignancy.
出处
《中国癌症杂志》
CAS
CSCD
1997年第4期234-236,共3页
China Oncology
